Operator: And we will take our next question from Andrew Mok with UBS. Your line is open.
Andrew Mok: Hi, good morning. The 2023 revenue guide of $700 million to $750 million, I think is about $70 million to $120 million below the proxy revenue in the deal filings. Can you help us understand the change in that outlook and the clinic expansion built into the 2023 revenue guide versus your previous expectations of I think 25 new clinics for 2023? Thanks.
Carlos de Solo: Maybe I’ll take the first part, I think when you think about our revenue, it’s all about our glide path to risk. So, we wanted to make sure that we guided conservatively, as we shift our membership from partial risk to full risk, the company’s taken a prudent approach, which is put us in a very, very strong position to not have those, that deterioration in an earnings from assuming risk too early. So, I think what you’re seeing there is that is our ability to increase that revenue will come, if we elect to take risks sooner. Generally, our contracts are taking risk from 18 months to a 24 months period, but we have the ability to trigger risk before that, depending on if we have favourability in those specific markets.
So, there is the opportunity for favourability in that in that guidance, but we want to make sure that we’re getting prudent because it could definitely carry over to the first quarter of the following year, et cetera. So, we just want to make sure that we’re taking that same kind of prudent conservative approach as we guide to revenue moving forward
Andrew Mok: And do you expect to open the same level of clinics for 2023? Maybe just any color?
Carlos de Solo: Well, we’re going to be doing with our clinics and I’ve said this on previous calls is we’re going to be very opportunistic now on how we open clinics, we’re still in growth mode, but because of the fact that we now have this very large MSO, we’re looking at areas where we have that density in those specific markets, and identifying those physicians that have sizable panels between 100 and 300 Medicare Advantage members so that we can open what we call seated de novo, and this is really going to allow us to open in a capital efficient way. So, we don’t have that cash burn on the OpEx that really affects those de novo in those first several years and with 2000 physicians under our platform, we think there’s going to be a lot of exciting opportunities this year.
Andrew Mok: And then on the 2024 MA rate notice, we’d love to hear your preliminary thoughts on the impact to your business and where you think you sit in relation to the minus 3% industry risk model adjustment? Thanks.
Kevin Wirges: Hi, Andrew it’s Kevin. Yeah, we’re still in the process of evaluating I think there’s still one it’s, the initial call letter, want to understand how the finals is going to shake out. The other pieces as we’ve had a significant growth this year, it’s very important to understand exactly which HCC is these new patients have attributed. And so, as we get those final estimates or the actual final suites that come in mid-year for 2022 payment year, which will reflect specifically which HCCs those new patients have. We have a good understanding of them, but there’s additional HCCs that are coming in from specialists and hospitals as well. And so, from our standpoint, we want to make sure that we have all the data when we aggregate that information, more to come on that one.
Operator: And we’ll take our next question from Jailendra Singh with Truist Securities. Your line is open.
